

CC Sage Capital Equity Plus Fund (APIR: CHN8862AU)

October 2025

Class A

Fund Performance

Returns¹	1 month	3 months	CYTD	FYTD	1 year	3 years p.a.	5 years p.a.	Since inception p.a. (20-Aug-2019)
Fund Net Return	-0.47%	-0.33%	7.87%	2.57%	9.30%	11.26%	14.14%	11.78%
Benchmark Return ²	0.39%	2.70%	11.88%	5.12%	12.46%	13.08%	12.64%	9.05%
Active Return (After fees)	-0.86%	-3.03%	-4.01%	-2.55%	-3.16%	-1.82%	1.50%	2.73%

About Sage Capital

As an Australian equities long short manager, Sage Capital views the market through eight unique Sage Groups enabling the team to focus on individual stock drivers and hedge systematic market risks. This style and cycle neutral investment process is designed to deliver consistent returns regardless of the market environment.

The Sage Capital investment team owns 100% of the firm and invests alongside its clients.

About the Fund

The CC Sage Capital Equity Plus Fund aims to achieve positive returns in excess of the S&P/ASX 200 Accumulation Index, after fees and expenses, over the long term by taking both long and short positions in selected Australian shares.

Fund Facts


1 011011 01010			
Investment Style	An Australian equity active extension long short strategy		
Net Asset Value	\$603.5 million ³		
Inception Date	20 Aug 2019		
Benchmark	S&P/ASX 200 Accumulation Index		
Management Fee	0.79% p.a.⁴		
Administration Fee	0.10% p.a.⁴		
Performance Fee	20.5% p.a.⁵		
High Water Mark	Yes		
Distributions	Semi-annually at 31 December and		

30 June


Portfolio Metrics

As at end of month		
Long exposure	125%	
Short exposure	-26%	
Gross exposure	151%	
Net exposure	99%	
Number of long positions	122	
Number of short positions	57	
Since Inception		
Information Ratio ⁶	8.0	
Tracking Error ⁶	3.5%	

Contributors to Fund Performance*



Allocation Weights*



Platform Availabilty

AMP MyNorth	ANZ Grow Wrap	Ausmaq
BT Panorama	Colonial First Wrap	Colonial FirstChoice
HUB24	IOOF eXpand	IOOF Pursuit
Macquarie Wrap	Mason Stevens	Netwealth
Praemium	Xplore Wealth	

Contact Details

Phone: 1800 940 599

Email: clientservices@channelcapital.com.au

Web: www.sagecap.com.au

¹ Performance is for the CC Sage Capital Equity Plus Fund ('the Fund') - Class A, and is based on month end unit prices in Australian Dollars. Net return is calculated after management fees and operating costs. Individual investor level taxes are not taken into account when calculating net returns. This is historical performance data. The value of an investment can rise and fall and past performance is not indicative of future performance. ² Benchmark refers to the S&P/ASX 200 Accumulation Index. ³ Net Asset Value is calculated as Fund assets less Fund liabilities. ⁴ All figures disclosed include the net effect of GST and RITC. ⁵ Performance Fee of 20.5% (including the net effect of GST and RITC) based on outperformance of the Fund Benchmark, net of the Management Fee. ⁵ Refer to Definition of Terms at the end of the report.



CC Sage Capital Equity Plus Fund (APIR: CHN8862AU)

October 2025

Class A

Performance Review

The CC Sage Capital Equity Plus Fund returned -0.47% in October underperforming the S&P/ASX 200 benchmark by -0.86%, which returned 0.39%.

The Sage Group that contributed most to performance for the month was Yield, while the key detractors were the Resources and Defensives Sage Groups.

Positive contributors in the Yield Group were based on long positions in ANZ Group (ASX: ANZ +10%) which rallied after holding an investor day highlighting strong medium-term return and cost reduction targets by offering more details on how the bank would achieve its elimination of \$1.5 billion worth of expenses and Challenger (ASX: CGF +8%) which performed well after APRA released new capital standards which will boost returns in their annuity products.

In the Resources Group, underperformance was largely driven by the portfolio's current positioning in critical minerals where Sage Capital held long positions in rare earths and short positions in lithium stocks. There was a lot of volatility in the space with rare earths outperforming early until US President Donald Trump's meeting with Chinese President Xi Jinping where he got some concessions on export controls and the stocks gave up all their gains, while lithium finished on near highs based on hopes of stronger battery storage demand. Sage Capital's views and positioning remain unchanged on the Resources Group.

With underweight positions in Pilbara Minerals (ASX: PLS +31%) and Liontown Resources (ASX: LTR +19%) this did hurt portfolio performance. The lithium miners are now pricing in a long-term level where we've historically seen a lot of swing supply out of Africa as well as encouraging further expansion of low-cost brine projects. A long position in Santos (ASX: STO -6%) was also a drag on the portfolio as the takeover bid by XRG Consortium fell through.

In the Defensives Group, a long position in CSL (ASX: CSL -10%) was a detractor. Given recent share price weakness, Sage Capital has built a long position, with significant underlying value in the core immunoglobulin business, but a surprise downgrade on US vaccination rates raises questions on company visibility of earnings and communication of current issues. However, it remains compelling value given the earnings upside as margins return to historical levels aided by cost reductions and the manufacturing efficiencies from the Horizon 1 & 2 programs.

Market Review

The S&P/ASX 200 index returned 0.39% in October.

In terms of Sage Groups, Resources and Global Cyclicals were strong while Growth and Domestic Cyclicals were the weakest. Leading into the month, markets globally had been on a strong run driven by enthusiasm on AI, dovish monetary tilts (even as inflation was rising again) and hope that the US tariff policy would either be not too painful or would moderate if it was.

Retail investor participation has seen the Russell 2000 Index surge, the ARK Innovation ETF up over 100% in 6 months, the most shorted stocks bouncing hard both in the US and Australia, while retail investors' favourite stock sectors were Lithium, Uranium, Rare Earths, Drone stocks and select Biotechs, which have all raced higher. Towards the end of the month, a few cracks emerged in investor confidence, a Bitcoin flash crash, concerns over the US fiscal position and challenging market valuations have seen tempered dip buying. Meanwhile, the US Government remains in shutdown and the ability of the government to unilaterally set tariff policy is being questioned by the US Supreme Court.

Fund Disclosures

Key service provider changes Nil
Key individual changes Nil
Risk profile or investment strategy material changes Nil

*Sage Capital uses a custom grouping system for long short positions (Defensives, Domestic Cyclicals, Global Cyclicals, Gold, Growth, REITs, Resources and Yield). With a focus on the principal macro earnings drivers for each stock, Sage Groups allow for comparisons to GICS for selecting stocks within a sector. Contributors to Active Performance is Gross of Fees.

Definition of Terms:



CC Sage Capital Equity Plus Fund (APIR: CHN8862AU)

October 2025

Class A

The information contained in this report is provided by the Investment Manager, Sage Capital Pty Ltd ACN 632 839 877 AR No. 001276472 ('Sage Capital'). Channel Investment Management Limited ACN 163 234 240 AFSL 439007 ('CIML') is the Responsible Entity and issuer of units in the CC Sage Capital Equity Plus Fund ARSN 634 148 913 ('the Fund'). Neither CIML nor Sage Capital, their officers, or employees make any representations or warranties, express or implied as to the accuracy, reliability or completeness of the information contained in this report and nothing contained in this report is or shall be relied upon as a promise or representation, whether as to the past or the future. Past performance is not a reliable indication of future performance. This information is given in summary form and does not purport to be complete. Information in this report, should not be considered advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling units in the Fund and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice. Readers are cautioned not to place undue reliance on forward looking statements. Neither CIML nor Sage Capital have any obligation to publicly release the result of any revisions to these forward looking statements to reflect events or circumstances after the date of this report. For further information and before investing, please read the Product Disclosure Statement available from www.sagecap.com.au and www.channelcapital.com.au. A Target Market Determination for the Fund is available at www.channelcapital.com.au.